ISSN 1507-6164 © Am J Case Rep, 2013; 14: 467-470 DOI: 10.12659/AJCR.889561

Case Reports

American Journal

Received: 2013.07.13 Accepted: 2013.08.13 Published: 2013.11.08

Authors' Contribution: Study Design A Data Collection B Statistical Analysis C Data Interpretation D Manuscript Preparation E Literature Search F Funds Collection G A case of *Helicobactor pylori* negative low-grade gastric MALT lymphoma in an elderly female, successfully treated with rituximab

AEF 1 Naba Raj Mainali EF 1 Madan Raj Aryal F 2 Ravi Shahu Khal EF 1,3 Richard Alweis Department of Medicine, Reading Health System, West Reading, PA, U.S.A.
Department of Medicine, Queens Hospital Center, Queens, NY, U.S.A.
Jefferson Medical College, Philadelphia, PA, U.S.A.

Corresponding Author:	Naba Raj Mainali, e-mail: nabaraj823@gmail.com
Patient: Final Diagnosis: Symptoms: Medication: Clinical Procedure: Specialty:	Female, 91 Low-grade gastric MALT lymphoma Recurrent epigastric and right upper quadrant dyscomfort Rituximab esophagogastroduodenoscopy • gastric biopsy Gastroenterology
Objective:	Unusual or unexpected effect of treatment
Background:	Mucosa associated lymphoid tissue (MALT) lymphoma can occur in any extranodal organ or tissue, stomach being the common site. Most of the gastric MALT lymphomas are related to chronic <i>H. pylori</i> infection. <i>H. pylori ri</i> negative gastric MALT lymphoma is relatively uncommon and usually treated with a short course of chemotherapy, radiotherapy or surgery.
Case Report:	Herein, we present a case of an elderly female with <i>H. pylori</i> negative, low-grade gastric MALT lymphoma that was successfully treated with a short course of rituximab.
Conclusions:	This case report emphasizes that rituximab monotherapy can be an effective treatment for <i>H. pylori</i> negative low grade gastric MALT lymphoma especially in an elderly patient where surgery or radiotherapy may not be appropriate.
Key words:	Mucosa Associated Lymphoid Tissue (MALT) • gastric lymphoma • chemotherapy • rituximab • surgery • radiation
Full-text PDF:	http://www.amjcaserep.com/download/index/idArt/889561

Background

The prevalence of *H. pylori* infection is approximately 90% in low-grade gastric MALT lymphoma [1]. In many cases, it is associated with other species of *Helicobacter* such as *H. felis* or *H. heilmannii* and hence true *H. pylori* negative gastric MALT lymphoma is a relatively uncommon diagnosis [2]. Among the available treatment options, such as radiotherapy, chemotherapy and surgery, our patient went into complete remission with a six-week course of rituximab therapy. However, it has been described in the literature that *H. pylori* eradication therapy can still be considered even in *H. pylori* negative MALT lymphoma [3].

Case Report

A 91-year-old Caucasian woman with past history of gastric ulcer thought to be secondary to aspirin usage 1 year prior to presentation and tubulovillous adenoma of the cecum presented to the emergency department complaining of recurrent epigastric and right upper quadrant discomfort. She also reported melena, fatigue and lightheadedness of several days duration. She denied nausea, vomiting, fever, chills, night sweats and weight loss. She was a lifetime non-smoker and denied any prior alcohol and recreational drug use. She denied any exposure to hazardous chemicals in the past. Family history was significant for a son diagnosed with colon cancer at the age of 45 years. Physical examination revealed normal vital signs. There was no evidence of lymphadenopathy, thyromegaly or mass. Abdominal examination revealed a soft, non-tender abdomen without hepatosplenomegaly. Digital rectal examination revealed hemoccult positive brown stool. Heart, lungs and neurological examinations were normal.

Laboratory findings revealed WBC count $7000/\mu$ L, platelets 247000/ μ L, Hemoglobin 11.2 gm/dL, sodium 137 meq/L, potassium 3.9 meq/L, bicarbonate 28 meq/L, Blood urea nitrogen (BUN) 7 meq/L, creatinine 0.75 mg/dL, blood sugar 98 mg/dL, bilirubin 0.6 mg/dL, AST 33 U/L, ALT 39 U/L and lipase 25 U/L. HIV 1 and 2 antibodies were negative. *H. pylori* IgG and IgM antibodies including cytotoxin-associated gene product A (Cag A) were negative. *H. pylori* stool antigen was also negative.

Esophagogastroduodenoscopy (EGD) revealed a 3 cm nonhealed gastric ulcer with smooth base but elevated borders in the lesser curvature of the stomach in the same location as it was found the year prior. Abdominal CT scan showed gastric wall thickening without any evidence of metastatic disease elsewhere. Histopathological examination of the biopsy specimen revealed dense lymphoid infiltration consistent with low-grade gastric MALT lymphoma (Figures 1–3); however culture and rapid urea test for *Helicobacter pylori* were negative, as they had been at the time of the initial finding of the ulcer the year prior.




Figure 1. Gastric body mucosa at 10× H&E stain showing dense lymphoid infiltrate.




Figure 2. Gastric body mucosa at 10× immunohistochemistry for CD20 showing strongly positive staining in the B lymphocytes of MALT lymphoma.




Figure 3. Gastric mucosa at 10× immunohistochemical stain for CD5 showing reactive T cells positively staining and negative staining in the B lymphocytes.

The patient was treated with pantoprazole 40 mg per oral twice daily, iron 364 mg once daily, and rituximab 375 mg/m² intravenous infusion once weekly for 6 weeks with gradual improvement in clinical symptoms. She did not have any side effects associated with rituximab. On follow up exam 3 months later, she was completely asymptomatic and her repeat EGD with biopsy was normal. Abdominal CT scan was negative for any mass and lymphadenopathy.

Discussion

MALT (Mucosa Associated Lymphoid Tissue) lymphoma was first described by Isaacson and Wright in 1983 [4]. MALT lymphoma can occur in any extranodal organ or tissue [5]. The incidence of Gastric MALT lymphoma is increasing and currently represents about 40% of all gastric lymphoma [6]. Most of the gastric MALT lymphoma are related to chronic *Helicobacter pylori* infection [7]. It has been incorporated into WHO lymphoma classification as marginal zone B-cell lymphoma of MALTtype [8]. Almost 5 to 10% of gastric MALT lymphomas are *H. pylori* negative and there is no clear explanation of its pathogenesis [9].

Though clinical presentation of low-grade gastric MALT lymphoma is vague and variable, most of the patients present with abdominal pain, dyspepsia, vomiting and gastric bleeding [10,11]. Our patient presented with epigastric discomfort, gastrointestinal bleeding as evidenced by hemoccult positive stool, fatigue and lightheadedness.

Every case of gastric MALT lymphoma must be tested for H. pylori infection by routine biopsies and/or rapid urease test, as approximately 90% of the cases are associated with it [7,8]. It has also been postulated that reduced number of H. pylori bacteria present in the infection may account for negative H. pylori and false negative results may be obtained if only one diagnostic test is utilized [12,13]. Diagnosis is confirmed by at least two negative tests for H. pylori as per the European guidelines [14]. If it turns out to be negative, serological analysis for H. pylori IgG antibodies and cytotoxin-associated gene product A (CagA) should be performed to identify truly negative gastric MALT lymphoma as there is a different therapeutic approach [8,15]. At the same time, other Helicobacter species such as H. felis or H. heilmannii should be excluded as treatment of these infections completely cure gastric MALT lymphoma [16,17]. EGD may reveal ulcerative, exophytic or

References:

infiltrative lesions [8]. EGD combined with endoscopic ultrasound or CT scan is employed for the accurate determination of extent of gastric wall involvement or involvement of perigastric lymph nodes [8,18].

H. pylori eradication therapy is the first-line therapy for *H. pylori* positive gastric MALT lymphoma but its role in *H. pylori* negative gastric MALT lymphoma remains controversial. *H. pylori* eradication therapy has been described in limited studies as initial therapy even in *H. pylori* negative gastric MALT lymphoma especially with a single lesion [3,12]. There is still no clear explanation for the effectiveness of *H. pylori* eradication therapy in *H. pylori* negative gastric MALT lymphoma [19]. Treatment options include chemotherapy with a short course of rituximab, radiation therapy, or, rarely, surgery in *H. pylori* negative gastric MALT lymphoma [6,20]. Several studies have shown more than 90% five year survival rate with surgical resection alone in low grade gastric MALT lymphoma which is also useful to obtain accurate clinicopathological staging [21–23].

Although there are no specific guidelines available in the current literature, rituximab can be offered as a monotherapy for a low grade gastric MALT lymphoma, especially in an elderly patient who cannot tolerate radiotherapy, surgery or conventional combined chemotherapy.

Conclusions

True *H. pylori* negative gastric MALT lymphoma can be diagnosed by at least two negative tests for *H. pylori*. Based upon our case report, rituximab monotherapy can be one of the treatment options for the condition with low side effect profile. However further study is required to develop the definitive guidelines for the management.

Acknowledgement:

We would like to thank Jettie Hunt, MD and April Reineke, Assistant Pathologist of the Department of Pathology at Reading Health System, Deb Sands of Digestive Disease Associates for their valuable contribution in obtaining histopathological slides.

Competing interests

The authors have no competing interest and no financial disclosure to make.

^{1.} Asenjo LM, Gisbert JP: [Prevalence of *Helicobacter pylori* infection in gastric MALT lymphoma: a systematic review]. Rev Esp Enferm Dig, 2007; 99(7): 398–404

Yang Y-Y, Lo S-S, Li FY et al: *Helicobacter pylori*-negative low-grade extranodal B-cell primary gastric mucosa-associated lymphoid tissue lymphoma. J Chin Med Assoc, 2007; 70(3): 121–25

- Asano N, lijima K, Terai S et al: Eradication therapy is effective for *Helicobacter* pylori-negative gastric mucosa-associated lymphoid tissue lymphoma. Tohoku J Exp Med, 2012; 228(3): 223–27
- Isaacson P, Wright DH: Malignant lymphoma of mucosa-associated lymphoid tissue. A distinctive type of B-cell lymphoma. Cancer, 1983; 52(8): 1410–16
- Bertoni F, Coiffier B, Salles G et al: MALT lymphomas: pathogenesis can drive treatment. Oncology (Williston Park, NY). 2011; 25(12): 1134–42, 1147
- Choi MK, Kim GH: [Diagnosis and treatment of gastric MALT lymphoma]. Korean J Gastroenterol, 2011; 57(5): 272–80
- Montalban C, Santon A, Boixeda D, Bellas C: Regression of gastric high grade mucosa associated lymphoid tissue (MALT) lymphoma after *Helicobacter pylori* eradication. Gut, 2001; 49(4): 584–87
- Morgner A, Schmelz R, Thiede C et al: Therapy of gastric mucosa associated lymphoid tissue lymphoma. World J Gastroenterol, 2007; 13(26): 3554–66
- 9. Hamajima N, Matuo K, Watanabe Y et al: A pilot study to evaluate stomach cancer risk reduction by *Helicobacter pylori* eradication. Am J Gastroenterol, 2002; 97(3): 764–65
- Kolve M, Fischbach W, Greiner A, Wilms K: Differences in endoscopic and clinicopathological features of primary and secondary gastric non-Hodgkin's lymphoma. German Gastrointestinal Lymphoma Study Group. Gastrointest Endosc, 1999; 49(3 Pt 1): 307–15
- Koch P, Probst A, Berdel WE et al: Treatment results in localized primary gastric lymphoma: data of patients registered within the German multicenter study (GIT NHL 02/96). J Clin Oncol, 2005; 23(28): 7050–59
- Park HS, Kim YJ, Yang WI et al: Treatment outcome of localized *Helicobacter* pylori-negative low-grade gastric MALT lymphoma. World J Gastroenterol, 2010; 16(17): 2158–62

- Gisbert JP, Aguado B, Luna M et al: Gastric MALT lymphoma: clinical characteristics and prevalence of *H. pylori* infection in a series of 37 cases. Rev Esp Enferm Dig, 2006; 98(9): 655–65
- Ricci C, Holton J, Vaira D: Diagnosis of *Helicobacter pylori*: invasive and noninvasive tests. Best Pract Res Clin Gastroenterol, 2007; 21(2): 299–313
- 15. Everhart JE, Kruszon-Moran D, Perez-Perez G: Reliability of *Helicobacter pylo*ri and CagA serological assays. Clin Diagn Lab Immunol, 2002; 9(2): 412–16
- 16. Fox JG: The non-*H. pylori* helicobacters: their expanding role in gastrointestinal and systemic diseases. Gut, 2002; 50(2): 273–83
- Morgner A, Lehn N, Andersen LP et al: *Helicobacter* heilmannii-associated primary gastric low-grade MALT lymphoma: complete remission after curing the infection. Gastroenterology, 2000; 118(5): 821–28
- 18. Ahmad A, Govil Y, Frank BB: Gastric mucosa-associated lymphoid tissue lymphoma. Am J Gastroenterol, 2003; 98(5): 975–86
- Raderer M, Streubel B, Wöhrer S et al: Successful antibiotic treatment of *Helicobacter pylori* negative gastric mucosa associated lymphoid tissue lymphomas. Gut, 2006; 55(5): 616–18
- Bautista-Quach MA, Ake CD, Chen M, Wang J: Gastrointestinal lymphomas: Morphology, immunophenotype and molecular features. J Gastrointest Oncol, 2012; 3(3): 209–25
- Kodera Y, Yamamura Y, Nakamura S et al: The role of radical gastrectomy with systematic lymphadenectomy for the diagnosis and treatment of primary gastric lymphoma. Ann Surg, 1998; 227(1): 45–50
- Bartlett DL, Karpeh MS Jr, Filippa DA, Brennan MF: Long-term follow-up after curative surgery for early gastric lymphoma. Ann Surg, 1996; 223(1): 53–62
- 23. Waisberg J, André EA, Franco MIF et al: Curative resection plus adjuvant chemotherapy for early stage primary gastric non-Hodgkin's lymphoma: a retrospective study with emphasis on prognostic factors and treatment outcome. Arq Gastroenterol, 2006; 43(1): 30–36